Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company that develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushings disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel Mab Xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alders clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The companys eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.
Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company that develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushings disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel Mab Xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alders clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The companys eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.
Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 4
List of Figures 5
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Alder Biopharma Raises US$38 Million In Series D Financing 11
Licensing Agreements 12
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 12
Equity Offering 12
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 12
Alder BioPharma Raises USD230 Million in Public Offering of Shares 14
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 15
Alder Biopharma Raises USD88.8 Million in IPO 17
Alder Biopharmaceuticals Inc - Key Competitors 19
Key Employees 20
Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 22
Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 24
Oct 27, 2016: Alder BioPharmaceuticals Announces Third Quarter 2016 Financial and Operating Results 26
Jul 26, 2016: Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results 28
Apr 28, 2016: Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results 30
Feb 23, 2016: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial and Operating Results 32
Corporate Communications 34
Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 34
Jun 29, 2016: Alder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer 35
Product News 36
Sep 06, 2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer 36
May 25, 2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention 37
Mar 06, 2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 38
Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization 39
Clinical Trials 40
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 40
Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 41
Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 42
Nov 28, 2016: Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine 43
Sep 15, 2016: Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress 44
Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention 45
Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine 46
Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society 48
Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention 49
Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List Of Tables
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alder Biopharma Raises US$38 Million In Series D Financing 11
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 12
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 12
Alder BioPharma Raises USD230 Million in Public Offering of Shares 14
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 15
Alder Biopharma Raises USD88.8 Million in IPO 17
Alder Biopharmaceuticals Inc, Key Competitors 19
Alder Biopharmaceuticals Inc, Key Employees 20
List Of Figures
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
RELATED REPORTS
Dermatology Drugs Global Market Forecast To 2022 Including: Acne, Dermatitis, Psoriasis, Others Covering: Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc
The dermatology drugs market consists of sales of dermatology drugs and related by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes
View ReportAcne Drugs Global Market Report 2020 Including: 1) By Type: Inflammatory Acne, Non-Inflammatory Acne 2) By End User: Hospitals & Clinics, Pharmacies & Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide Covering: ALLERGAN, Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc.
Acne Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global acne drugs market.Reasons
View ReportIpsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review
Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information
View ReportSienna Biopharmaceuticals Inc - Medical Equipment - Deals and Alliances Profile
Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a biopharmaceutical company that develops innovation therapies for inflammatory skin conditions and aesthetic conditions. It offers topical by design or low systemic exposure technology
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
